Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses

Inclusion Criteria: * Provision of signed written and dated informed consent * BMI between 19 and 30 kg/m2 * Subjects must be willing to use barrier methods of contraception Exclusion Criteria: * History of any clinically significant disease * Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product * History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs * Laboratory blood sample result showing elevated liver enzymes (ASAT, ALAT) and muscle enzymes (CK).